Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine.
A quadrivalent precursor to the pentavalent rotavirus vaccine candidate RotaTeq was evaluated in a 3-dose, 439-subject study. To determine immunogenicity, the quantity of rotavirus immunoglobulin A (IgA) in stool specimens obtained, at 1 of 10 study sites, from 37 placebo and 37 vaccine recipients was measured. None of the placebo recipients showed a clinically important (>/=3-fold) increase in stool rotavirus IgA, whereas 31 vaccine recipients showed an increase after at least 1 dose of vaccine. In total, 16, 19, and 15 vaccine recipients had increases after 1, 2, and 3 doses, respectively, indicating that a 3-dose regimen increased the immune response elicited by this vaccine.
Ward
Richard L
RL
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA. dick.ward@cchmc.org.
Bernstein
David I
DI
Smith
Vicki E
VE
Sander
Donna S
DS
Shaw
Alan
A
Eiden
Joseph J
JJ
Heaton
Penny
P
Offit
Paul A
PA
Clark
H Fred
HF
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D002417:Cattle; D004306:Dose-Response Relationship, Immunologic; D005243:Feces / Q000737:chemistry*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis* / Q000097:blood; D007223:Infant; D016865:Reassortant Viruses / Q000276:immunology*; D012401:Rotavirus / Q000276:immunology*; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014613:Vaccines, Attenuated / Q000008:administration & dosage* / Q000276:immunology
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated